Note: Ingredients listed on restricted chemical lists
EC/CAS
13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
>=0.1-<1
EC/CAS
121-79-9
Name of the chemical
Propyl 3,4,5-trihydroxybenzoate
Concentration
>=0.1-<1
General Information
Version
2.1
Revision date
2025-09-05
Product name
Aptivus capsules
Product Synonyms
Aptivus® capsules 250 mg, Elodius® capsules 250 mg with active ingredient: Tipranavir
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user
supplier name
Boehringer Ingelheim Pharmaceuticals Inc
Emergency telephone
+1 703-527-3887, +1 703-741-5970
Icons in SDS
Company Information
company name
Boehringer Ingelheim Pharmaceuticals Inc
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Other hazards
The pharmacological effect of the medicament has to be considered (see package leaflet) This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) This product does not contain titanium dioxide in its respirable form and would not be considered carcinogenic; however, upon crushing, grinding or other processing that could result in the gener- ation of respirable particulates, the Category 2 carcinogenic classification would apply.
Signal word
Warning
Hazard statements
H317 May cause an allergic skin reaction.
Prevention
P261 Avoid breathing dust. P272 Contaminated work clothing must not be allowed out of the workplace. P280 Wear protective gloves.
Response
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P363 Wash contaminated clothing before reuse.
Disposal
P501 Dispose of contents/ container to an approved waste dis- posal plant.
2.1 Classification of the substance or mixture
1910.1200) Hazards for the product as supplied Skin sensitisation : Category 1 Other hazards The pharmacological effect of the medicament has to be considered (see package leaflet). This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) This product does not contain titanium dioxide in its respirable form and would not be considered carcinogenic; however, upon crushing, grinding or other processing that could result in the gener- ation of respirable particulates, the Category 2 carcinogenic classification would apply.
